Back

PKP2 orchestrates OXPHOS expression in cardiomyocytes via a PGC1α-dependent mechanism

Han, S. J.; den Berg, D.; de Ruiter, H.; Tsui, H.; Kyriakopoulou, E.; Koopmans, T.; Perini, I.; Monshouwer-Kloots, J.; van Kampen, S. J.; te Riele, A. S. J. M.; Kelters, I. R.; Gianoli, M.; Burgering, B. M. T.; van Rooij, E.

2025-06-04 molecular biology
10.1101/2025.06.02.656790 bioRxiv
Show abstract

Arrhythmogenic cardiomyopathy (ACM) is an inherited cardiac disease where the majority of ACM patients carry a (likely) pathogenic variant in desmosomal genes, predominantly in plakophilin-2 (PKP2). While the genetic cause of the disease is well studied, the molecular disease-driving mechanisms and how exercise can drive disease progression remain poorly understood. In this study, we identified the oxidative phosphorylation (OXPHOS) pathway to be downregulated in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and human explanted hearts carrying pathogenic PKP2 variants. The reduced expression of OXPHOS related genes was a result of lower PPARGC1A expression which led to decreased mitochondrial spare capacity in PKP2 mutant hiPSC-CMs. Induction of PPARGC1A expression partially restored the expression of OXPHOS components and improved contractility in PKP2 mutant cells. These results suggest that improving oxidative capacity through modulation of PPARGC1A in cardiomyocytes could be considered as a new therapeutic target for ACM patients in the future.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.